Full-Time

Safety Sciences Director

Olema Oncology

Olema Oncology

51-200 employees

Clinical-stage biopharma targeting ER-positive breast cancer

Compensation Overview

$235k - $255k/yr

+ Equity + Bonus

San Francisco, CA, USA

In Person

Based in San Francisco or Boston; less than 10% travel.

Category
Medical, Clinical & Veterinary (1)

Get referred to Olema Oncology

Find people who can refer or advise you

Requirements
  • MD, PhD in the field of medical/biological science, PharmD, or RN degree
  • Small Molecule and Oncology is a must
  • Minimum of 8+ years of pharmacovigilance/drug safety experience in biopharmaceutical industry (for MD, PhD, or PharmD) or 10+ years (for RN)
  • Late phase clinical development and registration experience; NDA/BLA submissions and submission readiness planning
  • Experience with clinical safety data integration and Integrated Safety (ISS) authoring/review
  • Proven experience with benefit-risk assessments and regulatory justification
  • Experience with labeling negotiations and safety labeling strategy
  • Demonstrated success leading health authority meeting preparation and regulatory responses
  • Ability to apply FDA, EU and ICH guidelines governing pharmacovigilance activities and regulatory response management
  • Familiarity with clinical database/EDC, CTD/eCTD knowledge
  • Ability to work with the safety database for clinical/medical case review and simple queries
  • Experience working with business partners and managing safety vendors
  • Track record of leading, managing, mentoring and teaching new/junior team members
  • Participated in process improvement initiatives and SOPs related to safety
  • Must be able to manage time effectively, prioritize tasks, and meet deadlines
  • Strong verbal and written skills to convey safety findings clearly
  • Excellent analytical, problem-solving, strategic planning, and interpersonal skills
  • Self-motivated, fast learner, able to adapt in fast-paced organization
  • Sound judgment, professionalism, and strong ethical standards
Responsibilities
  • Lead the preparation of safety components for NDA/BLA submissions, ensuring alignment with FDA, EMA, and ICH requirements
  • Author and review integrated safety documents, including the Integrated Summary of Safety (ISS), Summary of Clinical Safety (SCS), benefit-risk assessments, and clinical overviews
  • Collaborate and support in the development of safety narratives, datasets, analyses, and submission-ready safety deliverables for regulatory filings
  • Conduct comprehensive evaluation and integration of safety data from clinical studies to support overall benefit-risk assessment for marketing applications
  • Collaborate with Clinical Development, Biostatistics, Regulatory Affairs, Medical Writing, and Programming teams to develop safety strategies and analyses supporting regulatory submissions
  • Prepare and review safety sections of key regulatory documents, including NDA/BLA modules, Investigator Brochures, protocols, informed consent forms, briefing books, and Company Core Data Sheets (CCDS)
  • Lead development and maintenance of Risk Management Plans (RMPs), Risk Evaluation and Mitigation Strategies (REMS), and other risk management documents as applicable
  • Participate in preparation and overall regulatory agency meetings, including safety briefing materials and responses to health authority questions
  • Partner with QA in regulatory inspections and audits, ensuring submission-related safety documentation is inspection ready
  • Review and interpret safety findings from clinical trials, literature, and post-marketing data to support regulatory decision-making and labeling recommendations
  • Contribute to the development of product labeling, including safety sections of prescribing information, package inserts, and related risk communication materials
  • Oversee aggregate safety reporting activities, including DSURs, PBRERs/PSURs, PADERs, and other periodic safety reports
  • Provide strategic safety input for submission timelines, filing readiness assessments, and regulatory risk mitigation plans
  • Ensure compliance with applicable FDA, EU, ICH, and global pharmacovigilance regulations governing clinical safety and marketing authorization applications
  • Lead cross-functional safety review meetings and communicate safety findings effectively to internal stakeholders, regulatory authorities, and external partners
Desired Qualifications
  • MD, PhD in the field of medical/biological science, PharmD, or RN degree (already in knowledge)
  • Experience in small molecule and oncology (already in knowledge)
  • Minimum of 8+ years (MD/PhD/PharmD) or 10+ years (RN) in pharmacovigilance/drug safety (already in knowledge)
  • Late phase clinical development and NDA/BLA submissions experience (already in knowledge)
  • Experience with ISS authoring/review (already in knowledge)
  • Proven experience with benefit-risk assessments and regulatory justification (already in knowledge)
  • Experience with labeling negotiations and safety labeling strategy (already in knowledge)
  • Demonstrated success leading health authority meeting preparation and regulatory responses (already in knowledge)
  • Ability to apply FDA, EU and ICH guidelines (already in knowledge)
  • Knowledge of CTD/eCTD and clinical database/EDC (already in knowledge)
  • Experience mentoring and leading junior team members (already in knowledge)
  • Process improvement initiatives and SOPs development (already in knowledge)
  • Ability to manage time, priorities, deadlines (already in knowledge)
  • Strong communication, analytical, problem-solving, planning, interpersonal skills (already in knowledge)
  • Self-motivated, fast learner in fast-paced environment (already in knowledge)
  • Sound judgment, professionalism, ethical standards (already in knowledge)

Olema Oncology develops targeted therapies for women’s cancers, with a focus on ER+/HER2- breast cancer. Its lead candidate palazestrant (OP-1250) is a dual CERAN/SERD that blocks estrogen signaling and promotes estrogen receptor degradation. The company is running a Phase 3 trial of palazestrant in combination with CDK4/6 inhibitors and has a collaboration with Novartis to test the therapy with ribociclib and everolimus. A second program, a KAT6 inhibitor, is in preclinical development, targeting epigenetic regulation.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2007

Get referred to Olema Oncology

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • OPERA-01 topline data expected H2 2026 could de-risk lead program and accelerate regulatory review
  • FDA Fast Track designation shortens regulatory timeline for palazestrant in post-CDK4/6 metastatic breast cancer
  • OP-3136 KAT6 inhibitor Phase 1 data at ASCO 2026 may validate synergistic dual-mechanism combination strategy

What critics are saying

  • OPERA-01 negative PFS readout in H2 2026 versus elacestrant would invalidate CERAN/SERD claim and kill pipeline
  • OPERA-02 failure to exceed 13.8 months PFS versus letrozole plus ribociclib collapses first-line positioning and partnership value
  • CFO departure since January 2026 increases risk of capital missteps delaying OPERA milestones and triggering dilutive down-round

What makes Olema Oncology unique

  • Palazestrant is a dual CERAN and SERD orally available for ER+/HER2- breast cancer
  • Olema uniquely targets ESR1-mutant resistance with complete ER antagonism blocking transcriptional activity
  • Company advances two Phase 3 trials: OPERA-01 monotherapy and OPERA-02 with Novartis ribociclib

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Stock Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Development Training Programs

Tuition Reimbursement

Professional Certification Support

Adoption Assistance

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Relocation Assistance

Bonus

Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
BioWorld
Apr 10th, 2026
Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers.

Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers. April 10, 2026 Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase CBL-B (CBLB)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety. They are described as potentially useful for the treatment of cancer.

Nasdaq
Mar 18th, 2026
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch

Key PointsCormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. |

GlobeNewswire
Mar 17th, 2026
Olema Oncology to present preclinical data for palazestrant and OP-3136 at the 2026 AACR Annual Meeting.

Olema Oncology to present preclinical data for palazestrant and OP-3136 at the 2026 AACR Annual Meeting. March 17, 2026 16:30 ET | Source: Olema Oncology SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present two preclinical posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California. Poster Presentation Details Title: Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha Poster/Abstract: 2950 Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs Date/Time: April 20, 2026, from 2:00-5:00pm PT / 5:00pm-8:00pm ET Title: Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures Poster/Abstract: 2949 Session: Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs Date/Time: April 20, 2026, from 2:00pm-5:00pm PT / 5:00pm-8:00pm ET About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com. About Palazestrant (OP-1250) Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib. About OP-3136 OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study. Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "anticipate," "believe," "could," "expect," "goal," "intend," "may," "on track," "potential," "upcoming," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics including but not limited to safety, tolerability, activity, efficacy and therapeutic effects of palazestrant or OP-3136, the combinability of palazestrant or OP-3136 with other drugs, including in the metastatic setting, and the timelines for enrollment for current clinical studies and for the receipt and presentation of results of clinical trials of palazestrant and OP-3136 each as a monotherapy and in combination trials. Because such statements deal with future events and are based on Olema's current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled "Risk Factors" in Olema's Annual Report on Form 10-K for the year ended December 31, 2025, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements. Media and Investor Relations Contact Courtney O'Konek Vice President, Corporate Communications Olema Oncology [email protected]

Yahoo Finance
Jan 31st, 2026
Olema Oncology CFO Shane Kovacs departs after six years with company

Olema Oncology, a clinical-stage biopharmaceutical company focused on breast cancer therapies, announced that Shane Kovacs, Chief Operating and Financial Officer, is leaving the company effective 30 January 2026 to pursue new opportunities. Kovacs will continue as a consultant through 1 August 2026. Kovacs joined Olema in 2020 and helped lead the company through late-stage clinical development of its lead candidate palazestrant whilst building the finance team and establishing a strong capital position. CEO Sean Bohen thanked Kovacs for his contributions and commitment. The company will immediately begin searching for a new Chief Financial Officer. Bohen will serve as interim Principal Financial Officer until a successor is appointed.

Insider Monkey
Jan 30th, 2026
LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA)

LifeSci Capital reiterates a Buy on Olema Pharmaceuticals (OLMA). Published on January 30, 2026 at 9:47 am by talha qureshi in news. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 26, Sam Slutsky from LifeSci Capital reiterated a Buy rating on the stock and raised the price target from $39 to $45. Earlier, on January 14, Kelsey Goodwin from Piper Sandler reiterated a Buy rating on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) with a price target of $40. Analysts at Piper Sandler noted that the bullish rating is based on the company's Palazestrant. Palazestrant is a potential best-in-class for treating ER+/HER2- breast cancer. The firm highlighted the drug's complete ER antagonism and ER degradation ability. These capabilities are expected to make the drug an upcoming treatment in the huge breast cancer market. In addition, the firm highlighted that the company is expecting multiple phase 3 trials in 2026, which are expected to add further upside to the stock. Piper Sandler expects Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) to launch Palazestrant by next year. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is focused on the development of treatments for patients with breast cancer and other serious diseases. Its key pipeline includes Palazestrant and OP-3136. While we acknowledge the potential of OLMA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OLMA and that has 100x upside potential, check out our report about this cheapest AI stock. Disclosure: None. This article is originally published at Insider Monkey.